RxDoctor Payments Data

Louis Heller, MD

Cardiovascular Disease · Kingston, NYNPI 1821084237

Payments from drug & device makers

$1,426in general payments, 2019–2025

Across 42 payments — averaging $33.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$234
  • Novartis$227
  • Abbott$193
  • Medicomp Inc$144
  • Boston Scientific$111
  • Biotronik Inc.$106
  • plus $409 from 9 others

What the payments were for

  • Food & beverage$1,29891%
  • Education$1289%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,426 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$114,452
Medicare patients
792
Services billed
1,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$129,366
XareltoRivaroxaban60$45,092
Praluent PenAlirocumab79$39,753
EntrestoSacubitril/Valsartan26$35,793
Repatha SureclickEvolocumab33$28,844
Repatha SyringeEvolocumab20$21,759
JardianceEmpagliflozin21$15,530
FarxigaDapagliflozin Propanediol11$6,129
Atorvastatin Calcium277$2,401
Metoprolol Succinate142$2,199
Ezetimibe38$984
Rosuvastatin Calcium42$824
Losartan Potassium78$635
ClopidogrelClopidogrel Bisulfate43$524
Valsartan18$511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$227$35,79326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →